Blog

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines

• Nebius Upside Expands as AI Feedback Loop Intensifies

Nebius Group (NASDAQ:NBIS) reported a sharply higher first quarter for 2026 as demand for AI computing capacity continued to outpace supply

Nexxen International (NASDAQ:NEXN) reported record first-quarter results for the three months ended March 31, 2026, and raised its full-year revenue outlook, citing stronger programmatic

Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal

Shares of Qualcomm Inc (NASDAQ: QCOM) are trading around $210 after one of their most explosive rallies in recent years. Just last month, the stock traded as low as $122, but earlier this week it

Kamada (NASDAQ:KMDA) reiterated its full-year 2026 outlook after reporting first-quarter results that management said were in line with expectations, excluding a temporary shipment delay that

• The Sell-Off In Kornit Digital May Set Up A 2nd Half Opportunity

Kornit Digital (NASDAQ:KRNT) reported first-quarter 2026 revenue at the high end of its guidance range and said customer activity is

KLX Energy Services (NASDAQ:KLXE) reported first-quarter 2026 revenue of $145 million and adjusted EBITDA of $11.1 million, with management describing the period as the likely low point for the

Algoma Steel Group (NASDAQ:ASTL) said its fiscal first quarter of 2026 marked a major operational transition as the company permanently halted blast furnace operations and continued ramping up its

• 3 Retailers Poised to Outmaneuver Tariff and Recession Concerns

Global-e Online (NASDAQ:GLBE) reported stronger-than-expected first-quarter 2026 results and raised its full-year outlook, citing

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate

• Buy the Dip: Top Tech Stocks Analysts Say Are Undervalued

Gilat Satellite Networks (NASDAQ:GILT) reported a stronger first quarter of 2026, with management citing broad-based revenue growth, margin

• MarketBeat Week in Review – 05/12 - 05/16

National Vision (NASDAQ:EYE) executives said the optical retailer’s first-quarter 2026 results showed progress in its transformation plan, with higher

Gladstone Investment (NASDAQ:GAIN) reported what management described as solid results for its fiscal fourth quarter and year ended March 31, 2026, citing portfolio growth, higher total investment

• 3 Small AI Stocks Ready to Explode (All Under $20)

Eos Energy Enterprises (NASDAQ:EOSE) reported a sharp year-over-year increase in first-quarter revenue and outlined a new project financing

• Why Oil Refiners Are the Real Winners of $100 Oil Prices

Eastern (NASDAQ:EML) reported lower first-quarter fiscal 2026 sales and earnings from continuing operations, as weaker demand for returnable

• DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital

CTW Cayman (NASDAQ:CTW) reported nearly flat revenue for the first half of fiscal 2026 while posting a GAAP net loss, as management said new game launches underperformed expectations and mature

• These 3 Psychedelic Stocks Activated After Trump's Executive Order

Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational

Brainsway (NASDAQ:BWAY) reported a strong start to 2026, with first-quarter revenue rising 35% year over year as the company expanded placements of its Deep TMS systems and continued to build its

• Light Speed Returns: Corning Cashes In on NVIDIA Growth

Applied Optoelectronics (NASDAQ:AAOI) expects a sharp second-half ramp in its data center optics business as demand for higher-speed

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised

Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center

• MarketBeat Week in Review – 11/4 - 11/8

Altimmune (NASDAQ:ALT) said it has strengthened its balance sheet and is preparing to begin a global Phase 3 trial of pemvidutide in metabolic

Bilfinger (ETR:GBF) confirmed its 2026 outlook after reporting a slower start to the year, with management pointing to severe winter weather and geopolitical uncertainty as factors that delayed